Cyduct Diagnostics Inc
CYduct Diagnostics, Inc., a healthcare company, develops, produces, and markets medical devices for the assessment, identification, diagnosis and treatment of breast cancer. The company offers HALO system, a noninvasive device that utilizes proprietary technology to obtain breast fluid; and MammoView, a fiberoptic technology with the ability to view and collect cells and other abnormalities. It a… Read more
Cyduct Diagnostics Inc (CYDX) - Total Assets
Latest total assets as of June 2025: $37.68K USD
Based on the latest financial reports, Cyduct Diagnostics Inc (CYDX) holds total assets worth $37.68K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cyduct Diagnostics Inc - Total Assets Trend (2016–2025)
This chart illustrates how Cyduct Diagnostics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cyduct Diagnostics Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Cyduct Diagnostics Inc's total assets of $37.68K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.2% |
| Accounts Receivable | $18.70K | 49.6% |
| Inventory | $17.77K | 47.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Cyduct Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyduct Diagnostics Inc's current assets represent 100.0% of total assets in 2025, an increase from 13.9% in 2016.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, up from 1.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 159.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 49.6% of total assets.
Cyduct Diagnostics Inc Competitors by Total Assets
Key competitors of Cyduct Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Cyduct Diagnostics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Cyduct Diagnostics Inc generates 1.88x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cyduct Diagnostics Inc is currently not profitable relative to its asset base.
Cyduct Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.03 | 1.78 |
| Quick Ratio | 0.01 | 0.02 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.18 Million | $ -1.81 Million | $ 180.07K |
Cyduct Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Cyduct Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -31.2% |
| Total Assets | $37.68K |
| Market Capitalization | $1.95K USD |
Valuation Analysis
Below Book Valuation: The market values Cyduct Diagnostics Inc's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cyduct Diagnostics Inc's assets decreased by 31.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cyduct Diagnostics Inc (2016–2025)
The table below shows the annual total assets of Cyduct Diagnostics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $37.68K | -31.18% |
| 2024-06-30 | $54.75K | -32.28% |
| 2023-06-30 | $80.85K | -72.75% |
| 2022-06-30 | $296.67K | +315.09% |
| 2021-06-30 | $71.47K | -30.18% |
| 2020-06-30 | $102.37K | -19.01% |
| 2019-06-30 | $126.40K | -18.64% |
| 2018-06-30 | $155.36K | -87.18% |
| 2017-06-30 | $1.21 Million | -0.60% |
| 2016-06-30 | $1.22 Million | -- |